Results 51 to 60 of about 8,267,805 (249)

Beyond the Number: Interpreting Prostate-Specific Antigen Elevation in the Context of Prostate Inflammation [PDF]

Urogenital Tract Infection
Prostate-specific antigen (PSA) is indispensable but not cancer specific; inflammation, benign prostatic hyperplasia, urinary retention, ejaculation, and instrumentation can all elevate PSA and complicate cancer risk assessment.
Byoungkyu Han, Ki-Hyuck Moon
doaj   +1 more source

Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer

Molecular Oncology, EarlyView.
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim, Maryam Aslam, Elouise Torruella, Alphons Sony, Asif Rahman, Simira Smith, Columba de la Parra, Moira Sauane   +7 more
wiley   +1 more source

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases

Asian Journal of Surgery, 2005
To review the pattern of initial clinical manifestation of patients who present with biochemically-advanced prostate carcinoma. Methods: A review of 39 prostate cancer patients with initial prostate specific antigen (PSA) levels of more than 400 ng/mL ...
Edmund Chiong, Alvin Fung Wean Wong, Yiong Huak Chan, Chong Min Chin   +3 more
doaj   +1 more source

Relationship between serum prostate-specific antigen and age in cadavers

SAGE Open Medicine, 2020
Objectives: An increase in number of unidentified cadavers is a growing problem. To identify these cadavers, a simple objective method is required to estimate cadaveric age.
Hajime Tsuboi, Daisuke Miyamori, Noboru Ishikawa, Hiroaki Ichioka, Hiroshi Ikegaya   +4 more
doaj   +1 more source

Prostate Specific Antigen (PSA): The Historical Perspective

McGill Journal of Medicine, 2020
In 1970, shortly after joining Roswell Park Memorial Institute, the New York State institute for the study of malignant diseases, the author initiated investigations on the use of tumor cell products for diagnosis and therapy of cancer.
T. Ming Chu
doaj   +1 more source

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Prostate specific antigen testing for prostate cancer

, 2002
Prostate specific antigen testing for prostate ...
Mary Dixon-Woods (7579535), Hazel Thornton (7580630)   +1 more
core   +3 more sources

68Ga–Prostate-Specific Membrane Antigen Uptake in a Malignant Pleural Effusion From Metastatic Prostate Cancer After Pleurodesis [PDF]

, 2019
A 76-year-old man with metastatic adenocarcinoma of the prostate presented with increasing dyspnea. After being treated initially with drainage and afterwards with pleurodesis, he was referred for Ga-prostate-specific membrane antigen 11 PET/CT imaging ...
Afshar Oromieh, Ali, Sachpekidis, Christos, Alberts, Ian Leigh, Rominger, Axel Oliver, Rominger A, Alberts I, Sachpekidis C, Afshar-Oromieh A   +7 more
core   +2 more sources

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source